Assessment of the long-term effect of vaccination on transmission of infectious bovine rhinotracheitis virus in cattle herds hyperimmunized with glycoprotein E–deleted marker vaccine

Bart Ampe, DVM; Luc Duchateau, PhD; Niko Speybroeck, PhD; Dirk Berkvens, PhD; Alain Dupont, MSc; Pierre Kerkhofs, PhD; Etienne Thiry, PhD; Marc Dispas, PhD

Objective—To assess long-term effects and risk factors for the efficacy of hyperimmunization protocols against infectious bovine rhinotracheitis (IBR) during a longitudinal field study of dairy and dairy-beef mixed farms.

Animals—Approximately 7,700 cows from 72 farms.

Procedures—Farms were assigned to 3 treatment groups (hyperimmunization groups [HIGs] 1 and 2, which were hyperimmunized with glycoprotein E (gE)–deleted marker vaccines, and a nonintervention group [NIG]). Cattle in HIG 1 were initially vaccinated with an attenuated vaccine, whereas cattle in HIG 2 were initially vaccinated with an inactivated-virus vaccine. Cattle in both HIGs received booster inoculations with inactivated-virus vaccines at 6-month intervals. The risk for gE seroconversion was compared among experimental groups via a shared frailty model with a piecewise constant baseline risk to correct for seasonal and secular effects.

Results—Risk for gE seroconversion significantly decreased over time for the HIGs, compared with the NIG. Seasonal changes in the risk of gE seroconversion were detected, with a higher risk during winter periods, compared with grazing periods. No significant difference was detected between HIGs 1 and 2. The only significant risk factor was the number of buildings for cattle on a farm; the higher the number of buildings, the lower the risk for gE seroconversion. Prevalence of IBR decreased over time in both HIGs but remained constant or increased in the NIG.

Conclusions and Clinical Relevance—Hyperimmunization via repeated administration of attenuated and inactivated-virus gE-deleted marker vaccines as well as inactivated-virus vaccines may provide a method for control of IBR. (Am J Vet Res 2012;73:1787–1793)
control strategy is based on repeated vaccination of all cattle in a herd. For the past 15 years, marker vaccines\(^6\)\(^7\) have allowed for the serologic discrimination between cattle infected with BHV-1 (seropositive against gE) and vaccinated cattle (seronegative against gE).\(^8\) Two field studies\(^9\)\(^10\) have been conducted over a period of 1 year to assess efficacy for the repeated administration of gE-deleted marker vaccine to cattle in dairy herds. Both compared results for repeated vaccination with results for placebo treatments. The authors concluded that the repeated use of live-virus\(^9\) or inactivated-virus\(^10\) vaccines reduces the incidence of gE seroconversion. Vaccination with a live-attenuated strain of virus resulted in a smaller reproductive ratio\(^11\) and was used to control IBR in the Netherlands. This strategy was later rejected because of vaccine contamination.\(^11\)

More recently, hyperimmunization protocols that involve the use of live-virus vaccines have been successfully tested in 149 herds, mostly large dairy farms.\(^12\)

Although a hyperimmunization protocol that involves the use of sequential administration of live-virus and inactivated-virus vaccines was found to be efficient,\(^13\) it has not been tested in farm settings. Currently, putative risk factors for BHV-1 infection have been estimated via cross-sectional observational studies.\(^3\)\(^4\)\(^14\)

Only randomized studies are able to determine that a risk factor is causative for the studied disease.

For the analysis of the study reported here, a new model for survival analysis was developed. The model was designed to take into account modification of the intensity of risk factors with time, clustering of animals in a herd, seasonal differences, and long-term change in risk over time (secular change). The objective of the study reported here was to assess in farm settings for a 28-month period the risk factors for BHV-1 infection in cattle herds hyperimmunized in accordance with a hyperimmunization protocols and compare them with those for herds without such interventions. We hypothesized that the infection rate in an HIG would decrease over time, compared with that for the NIG.

**Materials and Methods**

**Animals**—The study was conducted with cattle from 34 dairy herds and 38 dairy-beef mixed herds that were selected from a pool of 92 volunteer herds. Inclusion criteria for the herds were that farming activity was the only source of family income and that a herd comprised ≤ 180 cattle.

**Procedures**—Farms were assigned to 3 groups (HIG 1, HIG 2, and NIG) by use of a randomization procedure (lottery procedure). All of the cattle in HIG 1 and 2 were hyperimmunized. This consisted of an initial 2 administrations of marker vaccines (interval of 3 to 5 weeks between administrations), which were followed by booster vaccinations at intervals of approximately 6 months. To ensure identification of the treated cattle, vaccinations were performed at the start of the study (January 1997) and then successively shortly before the start of the cattle pasture periods and as soon as possible after the start of the cattle stabling periods for a period of 28 months.

Cattle in HIG 1 initially received 2 intranasal administrations of an attenuated gE-deleted marker vaccine.\(^4\)\(^8\) Cattle in HIG 2 initially received 2 SC administrations of an inactivated-virus gE-deleted marker vaccine.\(^3\)\(^4\) Both hyperimmunized groups received booster inoculations of the inactivated-virus vaccines,\(^3\)\(^4\) SC, at 6-month intervals. For the NIG, farmers used their usual vaccination schedules. All cattle of appropriate age for vaccination in each herd were included in the study. Only gE-deleted marker vaccines were used for all 3 groups, which allowed for serologic differentiation between infected and uninfected but vaccinated cattle.\(^8\)

**Seroologic monitoring**—To limit the amount of animal handling, serologic monitoring of all cattle was conducted via the same schedule as the vaccinations, which provided 6 cross-sectional blood sample collections of the 72 herds. Each blood sample was tested with an ELISA gE antibody test kit.\(^7\) Inconclusive results were considered as positive.\(^15\) Whenever possible, the serologic status of calves that had positive results because of maternal antibodies was adjusted to that of the first test value obtained after those calves were 6 months old. In all other cases, cattle that had at least 1 positive test result were definitively considered as latent carriers and positive cattle for subsequent measurements. Calves < 6 months old for which no subsequent sample was available were excluded because there was no further analysis to define their immune status. New cases of BHV-1 infection were defined as gE seroconversion during the interval since the preceding sampling period.

**Questionnaire for the risk factor analysis**—Each owner completed a questionnaire about the herd management practices potentially linked to the risk of BHV-1 infection; the questionnaire was completed during a face-to-face interview. The questionnaire was designed on the basis of results for studies\(^14\)\(^16\) of within-herd and between-herd risk factors and considered potential risk factors linked with herd management (ie, regular purchase of cattle, participation at fairs and shows, calf-dam relationship [whether calf was removed immediately after birth], use of artificial insemination or natural mating with bulls, and external sources of infection [ie, the presence of other farms within a radius of 100 m and possible contacts with other herds during the pasture period]).

**Descriptive epidemiology**—Six blood collections were performed for each herd during the study. For each sample collection, seroprevalence was estimated as the ratio of the number of gE-seropositive cattle to the number of cattle from which blood samples were collected.

**Data analysis**—Data analysis was conducted to account for cattle lost to follow-up monitoring, clustering of data collected at the same farm (all cattle in a herd were managed in the same manner [random effect]), season (animal density differed between winter [stabling period] and summer [grazing period]), natural turnover of cattle (birth of calves and purchase of cattle were balanced against death, culling, and sale of cattle, which resulted in a continuous entrance of cattle into and exit of cattle from the study population), and long-term change of the risk ratio over time.
A survival model is the most appropriate technique to use for analysis of time-to-event data (e.g., time to seroconversion). The expected seasonal effect was corrected by assuming 2 seasons/y (i.e., summer and winter), each of which had a different constant baseline risk. This simple model was extended with a random effect for each farm, \( u_i \). The shared frailty was assumed to follow a 1-parameter gamma-distribution with a mean of 1 and variance of \( \theta \). This meant that an average frailty (\( u_i \) equal to 1) had no effect on the risk for seroconversion. This resulted in a piecewise constant baseline risk shared frailty model defined by the following equation:

\[
h_{ij}(t) = (\lambda_1 \cdot I[t < 153] + \lambda_2 \cdot I[153 < t < 335] + ... \cdot u_i \cdot \exp(\alpha + \beta \cdot x_{ijt})
\]

where \( h_{ij}(t) \) is the risk for seroconversion at time \( t \) for cow \( j \) on farm \( i \) with covariates \( x_{ijt} \) at time \( t \); \( \lambda_1, \lambda_2, ... \) are the baseline risks for period 1, 2, ..., I is the indicator function, which is 1 if the condition is true and 0 if the condition is false; 153, 335, ... are the boundaries of the seasons in number of days; \( \exp(\alpha) \) is the difference in risk at the start of the study between the HIGs and the NIG; and \( \beta \) is the effect of an HIG over time. The baseline risk for each group was the baseline risk of the NIG multiplied by \( \exp(\alpha) \). The differences at the start of the study were not expected to be significant.

Comparison of the time to seroconversion of the HIG cattle with that of the NIG was used to establish the secular change in the time to seroconversion since the start of the hyperimmunization protocol on a farm. This implied that most cattle entered the study at a time different from 0. Only the period starting at the entrance of an animal \( y_{ij0} \) until an event or censoring time \( y_{ij} \) may have an effect on the cumulative risk. Therefore, the risk function was integrated from \( y_{ij0} \) to \( y_{ij} \) as follows:

\[
H_{ij}(y_{ij}) = \int_{y_{ij0}}^{y_{ij}} h_{ij}(t) \cdot dt
\]

The \( \beta \) values for HIG 1 and HIG 2 were an indication of the change in the risk over time. However, if

<table>
<thead>
<tr>
<th>Blood sample No.†</th>
<th>HIG 1</th>
<th>HIG 2</th>
<th>NIG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2,140 (20)</td>
<td>2,379 (20)</td>
<td>3,307 (32)</td>
</tr>
<tr>
<td>2</td>
<td>2,194 (20)</td>
<td>2,449 (20)</td>
<td>3,337 (32)</td>
</tr>
<tr>
<td>3</td>
<td>2,169 (20)</td>
<td>2,383 (20)</td>
<td>3,284 (32)</td>
</tr>
<tr>
<td>4</td>
<td>2,152 (20)</td>
<td>2,311 (20)</td>
<td>3,208 (32)</td>
</tr>
<tr>
<td>5</td>
<td>2,086 (20)</td>
<td>2,278 (20)</td>
<td>3,162 (32)</td>
</tr>
<tr>
<td>6</td>
<td>1,688 (19)</td>
<td>1,797 (19)</td>
<td>1,718 (20)</td>
</tr>
</tbody>
</table>

*Table 1—Number of cattle (No. of herds) in each of 3 experimental groups* that were tested for gE seroconversion at 6 successive blood sample collections.

Figure 1—Change in the mean gE seroprevalence of cattle in 3 experimental groups (HIG 1 [thin black line], HIG 2 [thick gray line], and NIG [dashed gray line]) as determined at each of 6 blood sample collections for dairy herds (A), female cattle of dairy-beef mixed herds (B), and male cattle of dairy-beef mixed herds (C). Cattle in HIG 1 were initially vaccinated with 2 doses of an attenuated vaccine, whereas cattle in HIG 2 were initially vaccinated with 2 doses of an inactivated-virus vaccine. Then, cattle in both HIGs received booster inoculations with inactivated-virus vaccines at approximately 6-month intervals. For the NIG, farmers used their usual vaccination schedules. Only gE-deleted marker vaccines were used for all 3 groups. To minimize cattle handling, blood samples were collected at the time of initial vaccinations (January 1997) and then at approximately 6-month intervals to coincide with 2 seasons (winter with stabilizing conditions and summer with grazing conditions).
The initial 2-dose vaccinations were administered at time 0. See Figure 1 for remainder of key.

Figure 1—Change in the risk ratio for gE seroconversion over time in dairy herds for HIG 1, HIG 2, and the NIG. Winter periods with stabled conditions (shaded areas) and summer conditions with grazing conditions (unshaded areas) are indicated. The initial 2-dose vaccinations were administered at time 0. See Figure 1 for remainder of key.

Table 2—Estimate (SE) for the coefficients of the piecewise constant risk model for dairy cows in 3 experimental groups.*

<table>
<thead>
<tr>
<th>Coefficient</th>
<th>Estimate</th>
<th>P value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>θ</td>
<td>1.563 (0.396)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>α</td>
<td>-0.148 (0.566)</td>
<td>0.793</td>
</tr>
<tr>
<td>HIG 1</td>
<td>-0.989 (0.627)</td>
<td>0.365</td>
</tr>
<tr>
<td>β</td>
<td>-0.734 (0.174)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HIG 2</td>
<td>-0.761 (0.197)</td>
<td>0.001</td>
</tr>
<tr>
<td>Building‡</td>
<td>-0.471 (0.182)</td>
<td>0.010</td>
</tr>
</tbody>
</table>

*Values were considered significant at P < 0.05. †Effect of an additional building for cattle on a farm. ‡Initial difference between the HIG and the NIG. §Change over time attributable to the HIG. θ = Variance among farms. See Table 1 for remainder of key.

Results

Animals—One farmer in HIG 1 and another in HIG 2 opted to leave the study before the last winter period because they considered the schedule for collection of blood samples to be excessively restrictive. In the NIG, 12 farmers left the study during the last period because they wanted to start a hyperimmunization program or were excluded because they wanted to modify the main type of production for their farm. Thus, at the end of the study, there were 19, 19, and 20 herds remaining in HIG 1, HIG 2, and the NIG, respectively (Table 1).

Dairy herds—Although the farms were randomly allocated to the various experimental groups, the mean seroprevalence at the start of the study was higher for HIG 1 (45%) than for HIG 2 (33%) and the NIG (35%; Figure 1). The gE seroprevalence decreased systematically in both hyperimmunized groups during the first 4 periods but remained almost constant in the NIG. During the last period, the gE seroprevalence increased slightly in HIG 1, remained constant in HIG 2, and markedly increased in the NIG.

The estimated risks of gE seroconversion over time were calculated (Figure 2). At the start of the study, the baseline risks were not significantly different for HIG 1 and HIG 2, compared with that for the NIG (α values for HIG 1 and HIG 2 were not significantly different from 0; Table 2). The risk ratio for gE seroconversion was higher for the NIG than for HIG 1 or HIG 2. In addition, increased protection with time was observed for both HIG 1 and HIG 2, as indicated by a change in the risk over time in HIG 1 and HIG 2, compared with that for the NIG (β values for HIG 1 and HIG 2 were negative and significantly different from 0). Although the reduction over time was slightly greater for HIG 2 than for HIG 1, there was no significant difference in the risk ratio for gE seroconversion over time between the 2 HIGs.

The decreasing risk was also evident by the change in the mean seroprevalence on a herd-level basis (Figure 2).
The seroprevalence in the HIGs primarily had a pattern of decreasing values, whereas the seroprevalence for the NIG remained almost constant.

Seasonal differences were determined by use of the risk for seroconversion for the NIG as the baseline value. The winter periods were always associated with a higher baseline risk than were the summer periods (Figure 2).

The estimated $\theta$ was 1.563 (Table 2). This corresponded to a Kendall $\tau$ of 0.439, which indicated a high correlation within the herds.

After consideration of all available risk factors, the final model revealed that only the number of buildings for cattle on a farm had an additional significant effect on the risk ratio. The greater the number of buildings on a farm, the lower the risk for gE seroconversion (risk ratio, 0.62/building).

**Dairy-beef mixed herds**—Although the farms were randomly allocated among the various experimental groups, the mean seroprevalence at the start of the study for the female population was lower for the NIG (36%) than for HIG 1 (56%) and HIG 2 (46%; Figure 1). In females, the baseline risk for seroconversion was significantly higher for the HIGs than for the NIG ($\alpha$ values for HIG 1 and HIG 2 were significantly $< 0$; Table 3). There was no significant difference in the baseline risk for gE seroconversion between HIG 1 and HIG 2. Over time, HIG 1 and HIG 2 had a large and significantly lower risk for seroconversion, compared with the risk for seroconversion for the NIG ($\beta$ values for HIG 1 and HIG 2 were significantly $< 0$), which indicated that the protection conferred by hyperimmunization increased over time and was twice as large as the value for dairy cattle.

In the male population, there were no significant differences between the 2 HIGs and the NIG at the start of the study or over time. Also, seasonal differences were less pronounced in the male population, compared with seasonal differences in female cattle of beef-dairy mixed herds and for the dairy herds (Figure 3).

Clustering had an important effect on the model, which indicated that herd management practices and environmental factors can have a major impact on the control of IBR. For female cattle in dairy-beef mixed herds, a value of 1.501 was estimated for $\theta$ (Kendall $\tau$, 0.429), which was similar to the values for the dairy herds. However, the estimated $\theta$ in beef bulls was 2.761, which was much higher than that of the female cattle and resulted in an extremely high intraclass correlation (0.580).

All risk factors were considered for the final model of female and male cattle of the dairy-beef mixed herds. However, none of them had a significant effect on the risk ratio for gE seroconversion.

### Discussion

The randomized longitudinal study reported here was based on the individual gE serologic follow-up monitoring of all cattle in 3 experimental groups on dairy and dairy-beef mixed farms. Two hyperimmunization protocols were used, and both significantly reduced the risk of BHV-1 infection in the females, compared with the risk for the NIG. However, it was not possible to detect the same effect in the male population of the dairy-beef mixed herds. These results are consistent with those obtained in previous field studies that revealed a reduction of virus circulation in cattle herds hyperimmunized with live-virus vaccine$^{9,12}$ or an inactivated-virus vaccine.$^{10}$

It is not possible to make further comparisons between results of other studies and those of the present study because conclusions of other studies were based on the reproduction ratio$^{15}$ calculated for a period of 18 months in studies in which only female cattle > 1 year old were included. By comparison, the present study was based on an analysis of the time to seroconversion in all cattle on the farms measured over shorter intervals and for a much longer period (28 months). In contrast to the calculation of the reproduction ratio, the proposed piecewise constant risk model estimates the
change in seroprevalence over time and takes into account clustering, different levels of risk over time, seasonal effects, and the development of herd immunity. This results in more information about the behavior of the infection, immunity on a herd-level basis, and differences between herds than does only a single summary measure such as the reproductive ratio.

Selection of the 2 hyperimmunization protocols was based on results of previous studies. The protocol for HIG 1 was based on the conclusions of an experimental trial13 that revealed successive administration of live-virus and inactivated-virus vaccines induced the production of antibodies and a cellular immune response, which were significantly higher than those obtained with only a single administration. The protocol for HIG 2 was based on the administration of an inactivated-virus vaccine, which had already been tested in a field setting, but for a shorter period.18 Both protocols were designed to prevent the development of major problems linked with the intensive use of live-attenuated virus vaccines. These problems include contamination of the vaccine by another virus, reactivation or re-excretion of a gE-negative vaccine strain in a field setting,19 and potential emergence of highly pathogenic gE-negative mutant strains of BHV-120 as a result of recombination between vaccine and field strains.

An NIG, rather than a placebo treatment, was used in the present study, even though it is more difficult to detect a significant difference between control and treatment groups. A placebo treatment was not acceptable because of the increased risk of virus circulation and infection, in comparison to the risk for the usual management procedures. In addition, it is unethical to force farmers to stop vaccinating cattle (ie, placebo treatment) for several years if their animals are selected for the control group. Thus, an NIG is commonly used to compare new treatments with standard treatments.21,22

In dairy herds, there were no differences in the initial risk ratio, but the change over time was significantly < 0 for the HIGs. This resulted in a decrease in risk over time for the HIGs, compared with that for the NIG. The risk of gE seroconversion for HIG 1 was always higher than, or equivalent to, that for HIG 2 (Figure 2); however, the differences were not significant. This observation is in agreement with results of a study16 in which animals hyperimmunized with inactivated-virus vaccines shed less virus after reactivation than did animals vaccinated with live-virus vaccine. This suggests that the most efficacious approach for the eradication of BHV-1 is the use of inactivated-virus vaccines to reduce reactivation, as opposed to the administration of live-virus vaccines in an attempt to prevent new infections. This strategy is also supported by results of another study.19

The increased risk for seroconversion during the winter periods, which was caused by commingling of cattle of various age classes and infection status in barns, revealed the limits of hyperimmunization in stressful situations. To be effective, hyperimmunization has to be applied for a long period (as indicated by the significant interaction between time and treatment; Tables 2 and 3). Even then, virus circulation cannot be totally stopped. Therefore, additional bio-security measures should accompany the use of hyperimmunization protocols. First, adult cows and heifers should receive booster inoculations of inactivated-virus gE-deleted IBR vaccine at least 15 days before the end of the grazing period. Second, whenever possible during the winter period, gE-seropositive cattle should be separated from cattle seronegative for gE. The present study revealed that there was a significant decrease in the risk for seroconversion when a farm had more buildings for cattle. In addition, as a general rule, calves should be immediately removed from their dams, and young stock should not have contact with dry (nonlactating) cows. This will allow for complete initial vaccination and booster administration before contact with a group of older animals, which are potential virus shedders. The specific accelerated removal of gE-seropositive cattle should be used to decrease the length of the hyperimmunization schedule.

In dairy-beef mixed herds, there was a difference between the female and male populations. For the female population, the findings were in agreement with those obtained for the dairy herd, although the risk ratio for seroconversion was significantly larger in the HIGs than in the NIG at the start of the study. This is probably attributable to the higher seroprevalence, and corresponding infection pressure, at the start of the study.

The risk of gE seroconversion in the HIGs decreased over time, compared with that for the NIG, and there was no significant difference between the 2 HIGs. The decrease over time in the females of the dairy-beef mixed herds was faster than that of the dairy herd. The higher seroprevalence for the HIGs at the start of the study is a possible explanation for this.

For the male population, we did not detect a significant difference in the change of the risk for gE seroconversion over time and the seroprevalence among the 3 groups, which had almost the same pattern. This may have been associated with an extremely high turnover rate associated with the management of feedlots (grouping of stressed cattle without previous testing for IBR and possible infection before optimal protection from vaccination). A reduction in infection pressure can be expected when the number of cattle shedding virus decreases among older animals as a result of hyperimmunization. In this category, a high clustering of infection times at the farm level was observed (high θ; Table 3), which resulted in a higher correlation within the herds for the male population than for the female population. This is indicative of large differences among the farms and suggested that the management of each farm and environmental factors can have a major impact on the control of IBR.

In the present study, we suggested that hyperimmunization that involved repeated administration of attenuated and inactivated-virus gE-deleted marker vaccine (HIG 1) as well as inactivated vaccines (HIG 2) allowed for the control of IBR. The efficacy of vaccinations can be maintained by appropriate management during the winter (cold season) and thus shorten the time until eradication of IBR.

a. Bayovac IBR-Marker vivum, provided by Bayer AG, Brussels, Belgium.
b. Rhinobovin Marker Live, provided by Intervet Inc, Brussels, Belgium.
c. Bayovac IBR Marker inactivatum, provided by Bayer AG, Brussels, Belgium.
d. Rhinobovin Marker inactivated, Intervet Inc, Brussels, Belgium.
e. HerdCheck, IDEXX, Westbrook, Me.

References